Accentia inks stretagic alliance with Baxter to acquire cyclophosphamide
Cyclophosphamide is the active drug used in Revimmune therapy, Accentia‘s proprietary system-of-care being developed for the treatment of a broad range of autoimmune diseases. The agreement also grants
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.